Tipelukast

Tipelukast (MN-001) is a small-molecule leukotriene blocker that MediciNova has been carrying through Phase 2 trials for over 15 years, now in a 40-patient study (NCT05464784) in non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes and hypertriglyceridemia, with co-primary endpoints of liver fat (CAP score) and fasting serum triglycerides at week 24 [1]. The bet is that the drug's anti-inflammatory and anti-fibrotic activity - the same target class as montelukast (Singulair) in asthma - translates to metabolic liver disease. A prior Phase 2a in NASH/NAFLD with hypertriglyceridemia (NCT02681055) was terminated early on a positive interim analysis showing significant triglyceride reduction (260.1 → 185.2 mg/dL after 8 weeks, p=0.00006), which is the real basis for repeating the lipid endpoint here [3]. In a field that was transformed in 2024 by resmetirom (Madrigal's Rezdiffra, the first approved MASH drug) and GLP-1s like semaglutide and tirzepatide delivering MASH resolution as off-target benefit of weight loss, tipelukast still faces steep competitive hurdles regardless of the readout [7].

Tipelukast has never been approved anywhere. MediciNova licensed the molecule from Kyorin Pharmaceutical (compound code reported as KCA-757; licensing terms not publicly verifiable) and has run Phase 2 studies in asthma, idiopathic pulmonary fibrosis (NCT02503657, completed; primary endpoint of forced vital capacity improvement was missed per published company-disclosed results) [2][9], and NASH/NAFLD lipid biology (NCT02681055, terminated early on positive interim for triglyceride and HDL endpoints) [3][10] without advancing to Phase 3. The current Phase 2 NCT05464784 (study code MN-001-NATG-202) enrolled 40 patients across NAFLD/T2D/hypertriglyceridemia; enrollment completed November 2025 and last patient visit occurred in May 2026, with topline data guided to Q3 2026 [11]. No FDA designations: no breakthrough, fast track, orphan, or RMAT. MediciNova's most recent 10-Q (filed May 2026, period ended March 31 2026) reports $27.3M cash, which management says funds operations through May 2027 (roughly 13 months runway); market capitalization is approximately $67M [6]. The 10-K (March 2026) continues to list MN-001 as an active program, but the company splits resources across multiple Phase 2 assets including ibudilast (MN-166) in ALS and progressive multiple sclerosis [5]. The 40-patient size across three overlapping metabolic conditions reads as a sign-finding study designed to justify a larger trial, not a registrational study.

Leukotrienes are inflammatory signaling molecules your immune cells release when they sense damage. They tighten airway smooth muscle (the cause of an asthma attack), pull in more inflammatory cells, and over time can drive fibrosis - scar tissue replacing healthy tissue. Tipelukast blocks the cysteinyl leukotriene receptor 1 (CYSLTR1), the same target as montelukast, and additionally inhibits 5-lipoxygenase (the upstream enzyme that synthesizes leukotrienes) and phosphodiesterases (enzymes that break down cyclic AMP, an intracellular brake on inflammation). Hitting three nodes in the pathway gives broader anti-inflammatory reach than montelukast's single mechanism. The NAFLD rationale: fatty liver isn't just about fat - it's about fat triggering chronic low-grade inflammation that damages hepatocytes and recruits stellate cells to lay down collagen scar. Leukotrienes are implicated in that cascade, and animal models show CYSLTR1 blockade reduces hepatic inflammation and fibrosis. The PDE inhibition arm separately has a clean rationale for lipid effects (PDE inhibition raises intracellular cAMP, which down-regulates triglyceride synthesis), and the prior NCT02681055 interim data are consistent with that mechanism doing real work on lipids in humans [3][10]. How strong is the case? Target-engagement biology is solid - montelukast is a multi-billion-dollar class, so we know CYSLTR1 antagonism does something in humans. But translating asthma mechanism to liver fibrosis is a real leap, and the prior IPF readout failed to slow lung function decline in a closely related fibrotic disease where the anti-fibrotic mechanism should have translated [2][9]. The multi-target profile (CYSLTR1 + 5-LO + PDE) cuts both ways: broader efficacy or dirtier pharmacology.

NCT05464784 (study code MN-001-NATG-202) is a randomized, double-blind, placebo-controlled Phase 2 in 40 patients with NAFLD due to T2D and hypertriglyceridemia, dosing 500 mg/day for 24 weeks [1][11]. The trial has co-primary endpoints: (1) change from baseline in liver fat content measured by CAP score (controlled attenuation parameter, a FibroScan-based ultrasound surrogate for steatosis), and (2) change from baseline in fasting serum triglycerides at week 24. Secondary endpoints include lipid profile (HDL-C, LDL-C, total cholesterol) and safety. Enrollment completed November 2025 and last-patient-last-visit was in May 2026; the company has guided topline data for Q3 2026 [11]. The design has clear limits. n=40 across three overlapping conditions is too small for a confident efficacy signal on the liver side, particularly when the liver endpoint is a surrogate for steatosis rather than histology. The FDA's current MASH guidance - anchored on resmetirom's 2024 accelerated approval - effectively requires biopsy-based histological endpoints (MASH resolution and fibrosis improvement) for any registrational program [7]. CAP correlates with steatosis but doesn't capture the inflammation or fibrosis that drive disease progression and regulatory decisions. The triglyceride co-primary is more defensible: a prior Phase 2a (NCT02681055) was terminated early on a positive interim analysis showing significant triglyceride reduction in NASH/NAFLD patients (260.1 → 185.2 mg/dL after 8 weeks, p=0.00006) with HDL increase and LDL decrease [3][10], so the lipid arm of this readout is a genuine attempt to confirm a real prior signal at a larger scale and longer duration. Even a clean win on triglycerides + CAP would be hypothesis-generating, not key - MASH approval requires histology.

Our model estimates a 5% chance this drug is eventually approved. To reach that number, it starts from the historical approval rate for Phase 2 drugs in this area - about 35% - then adjusts based on ten facts about the trial and sponsor. The estimate is pulled down mainly by the sponsor's weak approval record, limited earlier-phase results, heavier-than-usual blinding, and a randomized design. The remaining factors are close to average for this stage, so they don't move the number much.

Efficacy risk dominates. A statistically significant CAP score reduction tells you the drug shrinks liver fat but not whether it resolves MASH or reverses fibrosis - the histological endpoints that actually matter clinically and regulatorily. The IPF Phase 2 (NCT02503657) is the most directly relevant negative: tipelukast failed to slow forced vital capacity decline in idiopathic pulmonary fibrosis, with the company-disclosed result showing the primary endpoint was not met [2][9]. If it didn't work in lung fibrosis, the liver fibrosis hypothesis carries the same translation risk. The triglyceride co-primary is on firmer footing thanks to the prior NCT02681055 positive interim [3][10], but that earlier study was 8-12 weeks and open-label/small - a longer, blinded, placebo-controlled replication at 24 weeks is exactly the kind of trial where prior open-label signals often shrink. Safety risk is moderate. Montelukast's CYSLTR1 antagonism is generally well-tolerated, though FDA added a boxed warning for neuropsychiatric adverse events in March 2020 [8]. Tipelukast's broader PDE inhibition could add GI and CNS tolerability issues - roflumilast (PDE4 inhibitor for COPD) has weight loss and psychiatric AEs that limit uptake. Execution and financial risk: MediciNova reported $27.3M cash and an internally guided runway through May 2027 (~13 months) in the May 2026 10-Q [6], with market cap around $67M. That is enough runway to deliver the Q3 2026 readout but not enough to independently fund a Phase 3 MASH trial - a positive readout would have to be parlayed into a partnership or financing, both of which depend on the readout being strong enough to attract counterparties. 15+ years of Phase 2 work without Phase 3 advancement signals chronic execution friction [5]. Commercial risk is the biggest issue. Resmetirom (Rezdiffra) was approved March 2024 as the first MASH drug [7]. Semaglutide and tirzepatide deliver substantial MASH resolution as a byproduct of GLP-1-mediated weight loss, and both companies are running dedicated MASH trials. Tipelukast lacks both the head-to-head data and the differentiated mechanism story needed to win that competition even with a positive Phase 2.

Mostly noise, with one specific reason to keep half an eye on it. MediciNova has carried tipelukast for 15+ years without Phase 3 - that institutional pattern is not a vote of confidence in prior data. The current trial is exploratory (n=40, surrogate liver endpoint, lipid co-primary) and the IPF fibrosis readout was negative [2][9]. The competitive field was transformed by resmetirom and GLP-1s while MediciNova iterated on Phase 2 designs [7]. The specific signal worth checking: the triglyceride co-primary has real prior positive Phase 2a data behind it [3][10], so a confirmatory triglyceride win paired with a CAP reduction of meaningful magnitude (>30 dB/m vs placebo) would suggest the multi-target mechanism is doing real metabolic work and might justify a larger histology-anchored trial. Anything smaller is noise. Readout timing is concrete: enrollment completed November 2025, last patient visit May 2026, company-guided topline Q3 2026 [11] - that's the dated catalyst. With $27.3M cash and runway through May 2027 [6], MediciNova can deliver the readout but cannot independently fund a Phase 3, so a positive readout has to be partnered or financed to matter. The strongest tell would be a shift in MediciNova's public language: if MN-166 (ibudilast) gets more pipeline emphasis and MN-001 fades from the lead asset slot in investor materials, the company has lost confidence in tipelukast and you can stop tracking it.